Login to Your Account



Geron Hit Hard by Termination of Phase II Brain Cancer Trial

By Catherine Shaffer
Staff Writer

Tuesday, December 4, 2012
Shares of Geron Corp. fell 23 percent Tuesday on news that the Menlo Park, Calif.-based company discontinued development of its brain cancer drug GRN1005.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription